Neurocrine Biosciences Inc. (Nasdaq: NBIX) reported positive results from a Phase II Daisy PETAL study using elagolix in endometriosis patients sending the stock price soaring 89 cents to $3.62.
Positive Trial Results For Neurocrine Biosciences
May 25, 2010 at 13:58 PM EDT
